Published in N Engl J Med on July 29, 2004
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis (2009) 2.68
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Rate and predictors of treatment prescription for hepatitis C. Gut (2006) 2.31
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Hepatitis C treatment completion rates in routine clinical care. Liver Int (2009) 2.10
Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06
Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol (2006) 1.87
Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol (2007) 1.82
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol (2010) 1.78
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis (2012) 1.47
HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat (2008) 1.45
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat (2008) 1.40
Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol (2010) 1.33
Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr (2006) 1.32
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology (2012) 1.31
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med (2013) 1.28
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis (2008) 1.26
Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol (2009) 1.22
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction (2008) 1.20
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc (2011) 1.20
Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat (2007) 1.20
Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci (2006) 1.19
HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16
Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc (2011) 1.15
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis (2012) 1.14
The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat (2010) 1.11
Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients. BMC Infect Dis (2014) 1.11
Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS (2009) 1.10
Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interferon Cytokine Res (2010) 1.07
Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon (2011) 1.06
Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk. AIDS Patient Care STDS (2011) 1.05
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Management of chronic hepatitis C. Postgrad Med J (2005) 1.03
Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther (2008) 1.02
Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr (2010) 1.01
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2011) 0.99
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol (2009) 0.98
Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials (2009) 0.98
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol (2010) 0.98
Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med (2010) 0.97
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr (2010) 0.97
Treating hepatitis C in "difficult-to-treat" patients. N Engl J Med (2004) 0.96
Management of hepatitis C virus infection: the basics. Top Antivir Med (2012) 0.95
Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection. J Infect Dis (2007) 0.95
Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care STDS (2009) 0.95
HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. Clin Infect Dis (2008) 0.95
Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment. AIDS Patient Care STDS (2011) 0.95
Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr (2009) 0.94
Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Curr HIV/AIDS Rep (2012) 0.94
Chronic hepatitis C. Gut Liver (2011) 0.94
Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can J Gastroenterol (2008) 0.93
Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis (2012) 0.93
Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci (2011) 0.92
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis (2011) 0.92
Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis (2008) 0.92
Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep (2006) 0.91
HCV-HIV coinfection: simple messages from a complex disease. PLoS Med (2007) 0.91
Opioids and HIV/HCV infection. J Neuroimmune Pharmacol (2011) 0.91
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther (2011) 0.91
Morbidity and mortality profile of human immunodeficiency virus-infected patients with and without hepatitis C co-infection. Am J Trop Med Hyg (2006) 0.90
Hepatitis C treatment experiences and decision making among patients living with HIV infection. J Assoc Nurses AIDS Care (2009) 0.90
Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol (2010) 0.90
Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis (2013) 0.90
Successes and Challenges on the Road to Cure Hepatitis C. PLoS Pathog (2015) 0.90
Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India. J Clin Exp Hepatol (2014) 0.90
Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therap Adv Gastroenterol (2009) 0.89
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis (2010) 0.89
Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS (2005) 0.89
IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One (2011) 0.89
Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis (2015) 0.89
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med (2013) 0.89
The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther (2010) 0.89
Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol (2007) 0.88
Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat (2011) 0.88
Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates. PLoS One (2010) 0.88
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. J Infect Dis (2012) 0.88
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. J Natl Med Assoc (2005) 0.87
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment. AIDS Patient Care STDS (2009) 0.87
Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis (2010) 0.87
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J Acquir Immune Defic Syndr (2010) 0.87
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS (2014) 0.87
Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline. J Infect Dis (2012) 0.86
Effects of HCV treatment on cytokine expression during HCV/HIV coinfection. J Interferon Cytokine Res (2006) 0.86
Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials (2012) 0.86
Role of liver transplantation in human immunodeficiency virus positive patients. World J Gastroenterol (2015) 0.85
SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication. Antiviral Res (2012) 0.85
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis (2001) 5.27
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet (2001) 3.01
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1987) 2.24
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology (1999) 2.11
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS (2000) 1.97
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis (1999) 1.73
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest (2008) 6.17
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity (2002) 4.60
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One (2009) 4.52
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
A case for regulatory B cells. J Immunol (2006) 3.20
Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect (2003) 2.98
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology (2006) 2.96
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int (2002) 2.83
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 2.81
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet (2012) 2.69
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (2002) 2.59
Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A (2004) 2.57
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr (2006) 2.56
Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis (2011) 2.54
Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav (2004) 2.53
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
Inadequate coordination of maternal and infant HIV services detrimentally affects early infant diagnosis outcomes in Lilongwe, Malawi. J Acquir Immune Defic Syndr (2011) 2.38
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis (2010) 2.37
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Microalbuminuria in HIV infection. AIDS (2007) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology (2008) 2.13
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS (2010) 2.13
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (2007) 2.09
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08
Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis (2013) 2.02
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 1.99
Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol (2002) 1.98
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis (2010) 1.91
Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci U S A (2013) 1.89
Part-time careers in academic internal medicine: a report from the association of specialty professors part-time careers task force on behalf of the alliance for academic internal medicine. Acad Med (2009) 1.82
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med (2007) 1.81
Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology (2007) 1.80
Colitis is associated with thymic destruction attenuating CD4+25+ regulatory T cells in the periphery. Gastroenterology (2004) 1.78
Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defic Syndr (2008) 1.73
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo. Diabetes (2009) 1.70
Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.65
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis (2008) 1.63
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One (2010) 1.62
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Clin Infect Dis (2012) 1.56
Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS (2010) 1.54
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics (2012) 1.52
Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One (2007) 1.52
Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology (2010) 1.51
The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology (2006) 1.49
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab (2006) 1.49
Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med (2004) 1.48
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis (2007) 1.47
New therapies for hepatitis C virus infection. Clin Infect Dis (2009) 1.46
Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology (2002) 1.45
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res (2012) 1.45
Involving communities in the design of clinical trial protocols: the BAN Study in Lilongwe, Malawi. Contemp Clin Trials (2006) 1.45
Low absolute neutrophil counts in african infants. J Int Assoc Physicians AIDS Care (Chic) (2005) 1.44
Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol (2004) 1.43
Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis (2006) 1.43
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials (2003) 1.42
CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med (2007) 1.41
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS (2002) 1.39
Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS (2005) 1.39
Factors associated with early study discontinuation in AACTG studies, DACS 200. Contemp Clin Trials (2007) 1.39
Atg16l1 is required for autophagy in intestinal epithelial cells and protection of mice from Salmonella infection. Gastroenterology (2013) 1.38
Real-time electronic adherence monitoring is feasible, comparable to unannounced pill counts, and acceptable. AIDS Behav (2012) 1.38
Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology (2006) 1.38
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol (2002) 1.37
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med (2011) 1.37
Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med (2006) 1.36
Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol (2005) 1.36
Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology (2004) 1.36
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 1.32
Differences between international recommendations on breastfeeding in the presence of HIV and the attitudes and counselling messages of health workers in Lilongwe, Malawi. Int Breastfeed J (2006) 1.32